中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 4
Apr.  2017
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(4): 684-688

Effect of different minimally invasive therapies on the prognosis of patients with HBV-related primary liver cancer complicated by portal vein tumor thrombus

DOI: 10.3969/j.issn.1001-5256.2017.04.017

  • Center for Combined TCM and Western Medicine, Beijing Ditan Hospital, Capital Medical University

Research funding:

 

  • Published Date: 2017-04-20
    Abstract
  • Objective To investigate the effect of minimally invasive therapy on the 1-year survival of patients with HBV-related primary liver cancer ( PLC) complicated by portal vein tumor thrombus ( PVTT) , and to provide a guidance for clinical treatment. Methods A total of 191 patients who were diagnosed with HBV-related PLC complicated by PVTT in Beijing Ditan Hospital, Capital Medical University, from January 2012 to December 2014 and met the inclusion criteria were enrolled. The patients were followed up to observe their survival time, and they were divided into survival group and death group. The demographic features and related clinical indices were collected. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. The Cox regression model was used for multivariate analysis. Results Of all patients, 80 achieved a 6-month survival time, among whom 52 ( 65%) underwent minimally invasive therapy, and 57 achieved a 1-year survival time, among whom 36 ( 63. 16%) underwent minimally invasive therapy. In patients with HBV-related PLC complicated by PVTT, minimally invasive therapy had a significant effect on the 6-month survival rate ( χ2= 5. 419, P = 0. 009) and had no significant effect on the 1-year survival rate ( χ2= 1. 881, P = 0.093) , with a significant effect on survival time ( P = 0. 001) . The Cox multivariate analysis showed that direct bilirubin and gamma-glutamyl transpeptidase were risk factors for 1-year survival in patients with HBV-related PLC complicated by PVTT, while minimally invasive therapy was a protective factor for 1-year survival ( RR = 0. 812, 1. 007, and 1. 002, P < 0. 001, P = 0. 002, and P = 0. 017) . Conclusion Radiofrequency ablation combined with transcatheter arterial chemoembolization should be performed as early as possible for patients with HBV-related PLC complicated by PVTT and can prolong survival time.

     

    • FullText(HTML)
    • References(14)
  • [1]EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med, 2011, 365 (12) :1118-1127.
    [2] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.
    [3]ZHANG ZM, LAI EC, ZHANG C, et al.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J].Int J Surg, 2015, 20:8-16.
    [4]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma[J].Hepatology, 2005, 42 (5) :1208-1236.
    [5]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.
    [6]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
    [7]WANG ZH, HU K, TAO YM.Surgical treatment strategy for primary liver cancer with portal vein tumor thrombus:a report of 335cases[J].Chin J Gen Surg, 2015, 24 (7) :928-932. (in Chinese) 王志明, 胡宽, 陶一明.伴门静脉癌栓的原发性肝癌外科治疗:附335例报告[J].中国普通外科杂志, 2015, 24 (7) :928-932.
    [8]European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].Eur J Cancer, 2012, 48 (5) :599-641.
    [9]SCHWARZ RE, ABOU-ALFA GK, GESCHWIND JF, et al.Nonoperative therapies for combined modality treatment of hepatocellular cancer:expert consensus statement[J].HPB (Oxford) , 2010, 12 (5) :313-320.
    [10]KIM JH, YOON HK, KIM SY, et al.Transcatheter arterial chemoembolization vs.chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis[J].Aliment Pharmacol Ther, 2009, 29 (12) :1291-1298.
    [11]TSOCHATZIS E, MEYER T, O'BEIRNE J, et al.Transarterial chemoembolisation is not superior to embolisation alone:the recent European Association for the Study of the Liver (EASL) -European Organisation for Research and Treatment of Cancer (EORTC) guidelines[J].Eur J Cancer, 2013, 49 (6) :1509-1510.
    [12]KIM YS, RHIM H, LIM HK, et al.Intraoperative radiofrequency ablation for hepatocellular carcinoma:long-term results in a large series[J].Ann Surg Oncol, 2008, 15 (7) :1862-1870.
    [13]MONTORSI M, SANTAMBROGIO R, BIANCHI P, et al.Radiofrequency interstitial thermal ablation of hepatocellular carcinoma in liver cirrhosis.Role of the laparoscopic approach[J].Surg Endosc, 2001, 15 (2) :141-145.
    [14]ZHAO M, WANG JP, LI W, et al.Comparison of safety and efficacy for transcathere arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors[J].Natl Med J China, 2011, 91 (17) :1167-1172. (in Chinese) 赵明, 王健鹏, 李旺, 等.TACE联合射频消融与单独TACE治疗肝细胞癌的单支门静脉癌栓的安全性及疗效与预后因素分析[J].中华医学杂志, 2011, 91 (17) :1167-1172.
    • Relative Articles

  • Relative Articles

    [1]Kexin QIAO, Guiqin ZHOU, Yaxing LIU, Ying FENG, Yao LIU, Bin LI, Xianbo WANG. Clinical features of primary biliary cholangitis patients with negative or positive anti-mitochondrial antibody： A comparative study[J]. Journal of Clinical Hepatology, 2024, 40(9): 1778-1784. doi: 10.12449/JCH240910
    [2]Cui NaNa, Wang QiXia. Diagnosis and differential diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 724-727. doi: 10.3969/j.issn.1001-5256.2020.04.002
    [3]Zhang LiXia, Huang Xu, Sun XiaoJie, Zhang Ying, Lu ShaSha, Shi XiaoDong, Ji HuiFan, Guo XiaoLin. A case of antimitochondrial antibody-negative primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(1): 179-181. doi: 10.3969/j.issn.1001-5256.2019.01.038
    [4]Han Ying, Chen Jie, Dan Jing, Liu YanMin, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liu Dan, Huang YunLi, Huang ChunYang, Liao HuiYu. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1326-1329. doi: 10.3969/j.issn.1001-5256.2019.06.029
    [5]Liu HongLi, Yang YongFeng. Clinical and pathological features of primary biliary cholangitis with negative anti-mitochondrial antibody[J]. Journal of Clinical Hepatology, 2019, 35(3): 677-680. doi: 10.3969/j.issn.1001-5256.2019.03.051
    [6]Bian ZhaoLian, Shao JianGuo, Ma Xiong. Differential diagnosis of drug-induced liver injury and autoimmune hepatitis and related therapeutic strategies[J]. Journal of Clinical Hepatology, 2018, 34(6): 1156-1159. doi: 10.3969/j.issn.1001-5256.2018.06.003
    [7]Luo WenPing, Ma Hong, Zhao XinYan. Pathological features of hepatic vascular diseases and key points in differential diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2289-2294. doi: 10.3969/j.issn.1001-5256.2018.11.005
    [8]Jiang LiLin, Shen JianBo, Tang Hong, Lu ZhongHua. Pathological differential diagnosis of inflammatory liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2278-2282. doi: 10.3969/j.issn.1001-5256.2018.11.003
    [9]Du XiaoFeng, Ma ZhouPeng, Lin GuanSheng, He Hui, Tang YaRong, Wu JianMing. CT diagnosis and differentiation of nodular/mass-type hepatic lymphoma[J]. Journal of Clinical Hepatology, 2017, 33(8): 1492-1496. doi: 10.3969/j.issn.1001-5256.2017.08.016
    [10]Li Jing, Tang ShaoShan, Yu HongWei. Value of contrast-enhanced ultrasound in differential diagnosis of single metastatic liver cancer and solitary necrotic nodule of the liver[J]. Journal of Clinical Hepatology, 2016, 32(7): 1338-1341. doi: 10.3969/j.issn.1001-5256.2016.07.025
    [11]Wang Sui, Wang JiangBin. The diagnosis and treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1605-1607. doi: 10.3969/j.issn.1001-5256.2015.10.010
    [12]Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. Journal of Clinical Hepatology, 2015, 31(12): 1980-1988. doi: 10.3969/j.issn.1001-5256.2015.12.004
    [13]Zhang AnYuan, Chen Hao, Zhao Peng, Gong JianPing. Differential diagnosis of autoimmune pancreatitis from pancreatic cancer[J]. Journal of Clinical Hepatology, 2015, 31(5): 783-786. doi: 10.3969/j.issn.1001-5256.2015.05.038
    [14]Guo Jing, Xu LingFen, Sun Mei. Differential diagnosis of biliary atresia and intrahepatic cholestasis in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1252-1256. doi: 10.3969/j.issn.1001-5256.2015.08.017
    [15]Cao ZhangChun. Significance of combined analysis of autoantibodies in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 178-180. doi: 10.3969/j.issn.1001-5256.2015.02.008
    [16]Li YinPing, Niu JunQi. Significance of serum anti-gp210 antibody detection in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(5): 466-468. doi: 10.3969/j.issn.1001-5256.2014.05.023
    [17]Zhao DanTong, Liao HuiYu, Liu YanMin, Huang ChunYang, Zhang HaiPing, Sun LiMei, Ma YinXue, Zhao Yan, Yan HuiPing. ROC analysis of prognostic factors in Chinese patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(1): 62-66. doi: 10.3969/j.issn.1001-5256.2014.01.017
    [18]Li Bing, Shao Qing, Niu XiaoXia, Zhang Jian, Chen GuoFeng. Clinical features and diagnosis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2014, 30(5): 413-416. doi: 10.3969/j.issn.1001-5256.2014.05.007
    [19]Zhang Li, Bai ShiShan. Research progress on laboratory diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1109-1111+1120.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.4 %FULLTEXT: 15.4 %META: 75.2 %META: 75.2 %PDF: 9.3 %PDF: 9.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.7 %其他: 8.7 %其他: 1.8 %其他: 1.8 %Central District: 0.1 %Central District: 0.1 %China: 0.9 %China: 0.9 %India: 0.9 %India: 0.9 %Jamaica Plain: 0.1 %Jamaica Plain: 0.1 %Rochester: 0.1 %Rochester: 0.1 %Russian Federation: 0.1 %Russian Federation: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.6 %[]: 0.6 %上海: 3.2 %上海: 3.2 %东莞: 0.3 %东莞: 0.3 %临汾: 0.1 %临汾: 0.1 %丽水: 0.1 %丽水: 0.1 %佛山: 0.2 %佛山: 0.2 %信阳: 0.2 %信阳: 0.2 %北京: 3.3 %北京: 3.3 %南京: 0.9 %南京: 0.9 %南宁: 0.7 %南宁: 0.7 %南平: 0.1 %南平: 0.1 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %吉打州: 0.3 %吉打州: 0.3 %吉林: 0.4 %吉林: 0.4 %哥伦布: 0.1 %哥伦布: 0.1 %大连: 0.6 %大连: 0.6 %天津: 0.3 %天津: 0.3 %太原: 0.1 %太原: 0.1 %宝鸡: 0.2 %宝鸡: 0.2 %岳阳: 0.1 %岳阳: 0.1 %常德: 0.1 %常德: 0.1 %广州: 2.6 %广州: 2.6 %张家口: 5.1 %张家口: 5.1 %徐州: 0.1 %徐州: 0.1 %成都: 1.1 %成都: 1.1 %拉贾斯坦邦: 0.1 %拉贾斯坦邦: 0.1 %新泽西州: 0.3 %新泽西州: 0.3 %昆明: 0.7 %昆明: 0.7 %晋城: 0.1 %晋城: 0.1 %杭州: 1.0 %杭州: 1.0 %武汉: 1.2 %武汉: 1.2 %法兰克福: 0.2 %法兰克福: 0.2 %法拉盛: 0.2 %法拉盛: 0.2 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.2 %海得拉巴: 0.2 %深圳: 0.4 %深圳: 0.4 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %澳门: 0.3 %澳门: 0.3 %琼海: 0.2 %琼海: 0.2 %石家庄: 1.3 %石家庄: 1.3 %福州: 0.1 %福州: 0.1 %芒廷维尤: 35.6 %芒廷维尤: 35.6 %芝加哥: 0.1 %芝加哥: 0.1 %莫斯科: 2.2 %莫斯科: 2.2 %衢州: 0.1 %衢州: 0.1 %西孟加拉邦: 0.1 %西孟加拉邦: 0.1 %西宁: 14.7 %西宁: 14.7 %西安: 0.4 %西安: 0.4 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.8 %运城: 1.8 %通辽: 0.2 %通辽: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 1.4 %长春: 1.4 %长沙: 0.9 %长沙: 0.9 %阿什本: 0.3 %阿什本: 0.3 %香港: 0.3 %香港: 0.3 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他Central DistrictChinaIndiaJamaica PlainRochesterRussian FederationUnited States[]上海东莞临汾丽水佛山信阳北京南京南宁南平南阳卡纳塔克吉打州吉林哥伦布大连天津太原宝鸡岳阳常德广州张家口徐州成都拉贾斯坦邦新泽西州昆明晋城杭州武汉法兰克福法拉盛济南海得拉巴深圳湘潭漯河澳门琼海石家庄福州芒廷维尤芝加哥莫斯科衢州西孟加拉邦西宁西安贵阳赤峰运城通辽重庆长春长沙阿什本香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2149) PDF downloads(424) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[189]TodayPV[384]Online[25]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return